ClinicalTrials.gg
Not yet recruitingNCT07944092ENGAGEUpdated Nov 18, 2026

Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors

A Phase 1/2 interventional study of FMC-242 and Trastuzumab (or biosimilar) in Locally Advanced Solid Tumor, sponsored by Frontier Medicines Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Frontier Medicines Corporation · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
282
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are:

Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses?

Participants will need to come to the clinic to have the following:

  • Physical exams to see if there are any side effects
  • Standard lab tests to observe blood counts and other values
  • ECGs to measure heart signals
  • Blood drawn to measure how the drugs are being metabolized
  • Imaging such as CT scans to monitor if the cancer is growing or not
Read the detailed description

This is a first-in-human, Phase 1/2, open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability, PK, and anti-tumor activity of FMC-242 monotherapy and in combination in participants with locally advanced or metastatic solid tumors. FMC-242 is in a new class of drugs called PI3Kα:RAS breakers. The combination escalation cohorts may enroll while the monotherapy portion is still determining MTD/recommended dose for expansion (RDE).

This study is being conducted in two phases:

Phase 1 Dose Escalation: to determine the MTD and/or preliminary RP2D(s) and dosing regimen of FMC-242 monotherapy and in combination.

Phase 2 Cohort Expansion: to evaluate the efficacy and safety of FMC-242 at the RP2D(s) as a monotherapy and in combination in disease-specific cohorts.

After consenting to participate, participants will complete screening assessments during a Screening Period. Eligible participants will receive FMC-242 orally, at approximately the same time each day.

Depending on the tumor type, participants in combination cohorts will also receive the addition of another cancer drug administered per the local prescribing information/investigational labeling.

02

Conditions studied

  • Locally Advanced Solid Tumor

Keywords

  • PIK3CA mutant
  • PIK3CA amplified
  • HER2 positive mutant
  • HER2 positive amplified
  • RAS mutant
  • KRAS G12C mutant
  • ENGAGE
03

In context

Lead sponsor

Frontier Medicines Corporation is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of age ≥ 18 years at the time of signing the document.
  • No known downstream mutations in the AKT or RAS pathway
  • per v1.1.
  • Documented disease progression on, or disease recurrence after at least 1 line of standard of care (SoC) systemic treatment, including approved targeted therapy for patients with actionable mutations, or, in the opinion of the Investigator, would not be able to tolerate SoC therapy, or refused SoC therapy.
  • performance status 0-1.
  • Adequate hematological, renal, and hepatic function.
  • In Phase 1 only, must be willing to provide an on treatment tumor provided it is safe and medically feasible.
  • Women and men of must agree to use highly effective methods.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Has an archival tissue for retrospective confirmatory testing, unless discussed with the study Medical Monitor.

Exclusion criteria

Exclusion Criteria:

  • Prior use of a PI3Kα:RAS breaker (e.g., BBO-10203, VVD-159642).
  • Prior use of a RAS inhibitor (either pan-RASi or isoform-specific)
  • Received any systemic anti-cancer therapy or therapy within 21 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
  • Received radiation within 14 days prior to the first dose of study drug.
  • toxicity resulting from prior cancer therapies that have not returned to baseline or ≤ Grade 1
  • Known, uncontrolled central nervous system (CNS) .
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
  • Prior , requiring treatment or intervention, within the previous 3 years of study drug dosing, except for appropriately treated local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, which are allowed.
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    FMC-242 Monotherapy

    FMC-242 alone

    Drug: FMC-242

  • Experimental
    Combination Cohort A

    FMC-242 in combination with trastuzumab

    Drug: FMC-242 · Drug: Trastuzumab (or biosimilar)

  • Experimental
    Combination Cohort B

    FMC-242 in combination with fulvestrant

    Drug: FMC-242 · Drug: Fulvestrant (or generic)

  • Experimental
    Combination Cohort C

    FMC-242 in combination with a Pan (K)RAS inhibitor

    Drug: FMC-242 · Drug: Pan (K)RAS inhibitor

  • Experimental
    Combination Cohort D

    FMC-242 in combination with FMC-376

    Drug: FMC-242 · Drug: FMC-376

Interventions

  • DrugFMC-242

    PI3Kα:RAS breaker

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HER2 targeting agent

    Also known as: Herceptin

  • DrugFulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    selective estrogen receptor degrader

    Also known as: Faslodex

  • DrugPan (K)RAS inhibitor

    Pan (K)RAS inhibitor

  • DrugFMC-376

    KRAS G12C inhibitor (experimental)

06

What researchers measure

Primary outcomes

  1. Phase 1 and Phase 2: Adverse Events

    Number and grade of adverse events (AEs) with FMC-242 alone and in each of the combinations using CTCAE v 6.0

    Time frame: Approximately 24 months

  2. Phase 1 : Dose Limiting Toxicities

    Number of dose limiting toxicities (DLTs) with FMC-242 alone and in each of the combinations

    Time frame: Up to 21 or 28 days

  3. Phase 2: Overall Response Rate

    Assess the overall response rate (ORR) using RECIST 1.1 in participants treated with FMC-242 alone and in each of the combinations

    Time frame: Approximately 24 months

Secondary outcomes

  1. Phase 1: Assess anti-tumor activity

    To assess preliminary anti-tumor activity of FMC-242 alone and in combinations using RECIST v1.1

    Time frame: Approximately 24 months

  2. Phase 1: FMC-242 Maximum observed plasma concentration

    Measure the maximum observed plasma concentration (Cmax) for FMC-242

    Time frame: 6 weeks

  3. Phase 1: FMC-242 time to maximum observed plasma concentration

    Measure time to maximum observed plasma concentration (Tmax) for FMC-242

    Time frame: 6 weeks

  4. Phase 1: FMC-242 trough observed concentration

    Measure trough observed concentration (Cmin) for FMC-242

    Time frame: 6 weeks

  5. Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval

    Measure area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-t, AUCtau) for FMC-242

    Time frame: 6 weeks

  6. Phase 1: Terminal half-life

    Measure the terminal half-life (t1/2) for FMC-242

    Time frame: 6 weeks

  7. Phase 1: Apparent clearance

    Determine apparent the clearance (Cl/F) for FMC-242

    Time frame: 6 weeks

  8. Phase 1: Determine the volume of distribution

    Determine volume of distribution (Vd/F) for FMC-242

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Aggregate study data will be shared at the end of the study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2029, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944092
Lead sponsor
Frontier Medicines Corporation
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Aaron (Ron) Weitzman, CMO, MD
Contact
clinicaltrials@frontiermeds.com
650-457-1005
Aaron (Ron) Weitzman, MD
study director · Frontier Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion